( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



Qurbonov ?. ?.*, Gadayev ?. G., Nurillaeva N. M. and Turakulov R. I.


The aim of the study was to evaluate effects of angiotensin (АТ) II АТ1 – receptor antagonist representative azilsartan medoxomil and mineralocorticoid receptor antagonist eplerenone to clinical-hemodynamic indexes and serum levels of gelectin-3 and aldosterone in different hemodynamic phenotypes of chronic heart failure patients. The study involved 108 CHF patients: the 1st group consisted of 36 patients with reduced LVEF (LVEF<40%), the 2nd group - 34 patients with intermediate LVEF (LVEF 41 – 49%) and the 3rd group consisted of 38 CHF patients with preserved LVEF (LVEF>50%). Referent serum levels of fibrosis biomarkers were as following: G-3 - 8,6 [3,7;11,7] ng/ml, aldosterone - 86,8 [47,8;199,1] pg/ml. They were administered 40-80mg of azilsartan medoxomil and 25-50mg of eplerenone as a basis therapy for six months. In CHF patients serum levels of G-3 and aldosterone were initially higher compared to control group. Particularly, they were respectively 2,1 and 5,1 times higher in the 1st group patients; 2,2 and 6,2 times in the 2nd; 2,6 and 6,6 times in the 3rd group. After six months of basis treatment, consisting of azilsartan medoxomil and eplerenone combination there was reliable decrease in serum levels of G-3 and aldosterone. In the first group decrease was respectively 9, 1% and 14,2%, in the 2nd 12,4% and 18,6%, in the 3rd group 16,1% and 22,5%. This in turn led to regression of LV remodeling and TBF indexes: in the 1st group LV EDV decreased by 7,4%, ESV by 13,5%, while LVEF increased by 8,5%. In the 2nd group LV EDV decreased by 10%, ESV by 16,6%, while LVEF increased by 7,6%. In the 3rd group decreased by %, ESV decreased by 5,3%, while LVEF increased by 4,1% LV EDV by 1,5%. In patients of the 2nd and 3rd groups LVRWT and LVMI reliably decreased respectively by 4,6% and 2,0%; 6,5% and 3,8% after the treatment. In CHF patients with intermediate and preserved LVEF statistically significant increase of fibrosis markers such as G-3 and aldosterone compared to CHF patients with reduced LVEF, as well as finding of concentric remodeling and hypertrophy of LV indicates increased accumulation of excess collagen in extracellular matrix, myocardial stiffening and intensiveness of fibrosis processes. Concordance between decrease of fibrosis markers and regression of LV remodeling and TBF measurements, and improvement of clinical condition and life quality of and tolerance to physical stress of the patients indicates diminished amount of fibrosis in myocardim. which in turn suggests that combined use of azilsartan medoxomil and eplerenone in treatment of CHF patients would be more prudent.

Keywords: chronic heart failure, galectin – 3, aldosterone, fibrosis markers, azilsartan medoxomil, eplerenone [email protected]

[Full Text Article]




    AUGUST Issue has been successfully launched on 1 August 2022.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 August 2022 Issue has been Published, Kindly check it on

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database